| Glycogen synthase kinase 3: more than a namesake GV Rayasam, VK Tulasi, R Sodhi, JA Davis, A Ray British journal of pharmacology 156 (6), 885-898, 2009 | 606 | 2009 |
| NSD1 is essential for early post‐implantation development and has a catalytically active SET domain GV Rayasam, O Wendling, PO Angrand, M Mark, K Niederreither, L Song, ... The EMBO journal, 2003 | 404 | 2003 |
| Falling off the academic bandwagon: Women are more likely to quit at the postdoc to principal investigator transition ED Martinez, J Botos, KM Dohoney, TM Geiman, SS Kolla, A Olivera, ... EMBO reports 8 (11), 977-981, 2007 | 244 | 2007 |
| Fatty acid receptors as new therapeutic targets for diabetes GV Rayasam, VK Tulasi, JA Davis, VS Bansal Expert opinion on therapeutic targets 11 (5), 661-671, 2007 | 135 | 2007 |
| Ligand-specific dynamics of the progesterone receptor in living cells and during chromatin remodeling in vitro GV Rayasam, C Elbi, DA Walker, R Wolford, TM Fletcher, DP Edwards, ... Molecular and cellular biology 25 (6), 2406-2418, 2005 | 122 | 2005 |
| Subnuclear trafficking and gene targeting by steroid receptors AK Nagaich, GV Rayasam, ED Martinez, M Becker, Y Qiu, TA Johnson, ... Annals of the New York Academy of Sciences 1024 (1), 213-220, 2004 | 61 | 2004 |
| Exploring the potential of adjunct therapy in tuberculosis GV Rayasam, TS Balganesh Trends in pharmacological sciences 36 (8), 506-513, 2015 | 55 | 2015 |
| MmpL3 a potential new target for development of novel anti-tuberculosis drugs GV Rayasam Expert opinion on therapeutic targets 18 (3), 247-256, 2014 | 44 | 2014 |
| Identification of berberine as a novel agonist of fatty acid receptor GPR40 GV Rayasam, VK Tulasi, S Sundaram, W Singh, R Kant, JA Davis, ... Phytotherapy Research 24 (8), 1260-1263, 2010 | 35 | 2010 |
| Insights from a Pan India sero-epidemiological survey (phenome-India cohort) for SARS-CoV2 S Naushin, V Sardana, R Ujjainiya, N Bhatheja, R Kutum, AK Bhaskar, ... Elife 10, e66537, 2021 | 33 | 2021 |
| Development of a one-pot assay for screening and identification of Mur pathway inhibitors in Mycobacterium tuberculosis K Eniyan, A Kumar, GV Rayasam, A Perdih, U Bajpai Scientific reports 6 (1), 35134, 2016 | 30 | 2016 |
| Inhibition of Mycobacterium tuberculosis dihydrodipicolinate synthase by alpha-ketopimelic acid and its other structural analogues P Shrivastava, V Navratna, Y Silla, RP Dewangan, A Pramanik, ... Scientific reports 6 (1), 30827, 2016 | 27 | 2016 |
| An estrogen receptor chimera senses ligands by nuclear translocation ED Martinez, GV Rayasam, AB Dull, DA Walker, GL Hager The Journal of steroid biochemistry and molecular biology 97 (4), 307-321, 2005 | 25 | 2005 |
| A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys P Singh, R Ujjainiya, S Prakash, S Naushin, V Sardana, N Bhatheja, ... Computers in biology and medicine 146, 105419, 2022 | 13 | 2022 |
| 75 Years of India's Independence and 80 Years of CSIR SC Mande, GV Rayasam, G Mahesh NIScPR-CSIR, India, 2021 | 2 | 2021 |
| Role of S&T organisations in mitigation of Covid-19: CSIR as a case study GV Rayasam, SC Mande Indian Chemical Engineer 62 (4), 333-342, 2020 | 2 | 2020 |
| Innovation at OSDD–unconventional vs conventional approaches R Ummanni, S Ramchandran, A Kumar, GV Rayasam NISCAIR-CSIR, India, 2014 | 2 | 2014 |
| Communication in the times of COVID-19 GV Rayasam, SC Mande Current Science 120, 10-25, 2021 | 1 | 2021 |
| A machine learning-based approach to determine infection status in recipients of BBV152 whole virion inactivated SARS-CoV-2 vaccine for serological surveys P Singh, R Ujjainiya, S Prakash, S Naushin, V Sardana, N Bhatheja, ... medRxiv, 2021.12. 16.21267889, 2021 | | 2021 |
| Open Source Drug Discovery: Model for Novel Drugs against Neglected Diseases GV Rayasam, TS Balganesh NISCAIR-CSIR, India, 2014 | | 2014 |
